Zonagen (zona) - good buy? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: CalculatedRisk who wrote (3815)	5/3/1998 12:37:00 AM
From: Linda Kaplan	Read Replies (1) of 7041

Risk: On your first question, no, they're saying there was some measurable improvement from minimal to mild-moderate. But we don't know the definition (measurement) for either category. A double-blind crossover study is the best kind, if it's done correctly. The subjects don't know what they're getting and neither do the people giving them the meds. They will get the placebo and the drugs (I guess both dosages) at different times during the study and not know which they're getting. The testers also won't know. Of course, the details are crucial about this, to know that it's being done correctly. Like, it's ideal if the pills for the placebo and both doses of Vasomax look exactly the same and that the subjects not even know there is a switch. How carefully the details are formulated does count, but there is a wide range of what could really be done and still be "called" a double-blind crossover study. There should be a scientific paper of some size that provides this information, and much more, so that we could evaluate the validity of the study. What we have so far doesn't allow us to examine it or evaluate it. Linda

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next